Focal defect or widespread wear — why the distinction decides everything

The answer to whether ChondroFiller is suitable turns almost entirely on one question: does the joint retain enough healthy tissue to support repair? ChondroFiller is an acellular collagen scaffold — it does not deliver cells; instead, it provides a structured matrix that recruits the patient's own progenitor cells from the surrounding cartilage and subchondral environment. Where that cellular reservoir is depleted or the joint is actively hostile, the scaffold has nothing to work with, and the procedure carries risk without meaningful prospect of benefit.

The treatment is designed for focal, contained cartilage defects within an otherwise functional knee — not for joints where wear is diffuse or the biological environment is compromised. Suitability assessment exists to protect patients from exactly that scenario.

Exclusions fall across four broad categories: the joint environment itself, material compatibility with the device, unaddressed mechanical problems, and systemic health factors that impair healing. The outcome figures cited in clinical literature reflect patients who met all of these criteria — they do not apply to those who do not.

Diffuse osteoarthritis and bone-on-bone knees

Of all the reasons a patient may not qualify, widespread cartilage loss across more than one compartment of the knee is the single most important — and it is a categorical disqualifier, not a risk factor to be balanced against other considerations. The manufacturer lists multi-compartmental arthrosis as an absolute contraindication, meaning no degree of otherwise favourable assessment changes this outcome.

The reason is both structural and biological. In bone-on-bone wear, the cartilage that would normally border a focal defect has gone. Without intact surrounding tissue, the scaffold has no anchoring environment and — as noted above — no adequate local progenitor cell population to recruit. Placing the scaffold in this setting offers no meaningful path to repair; the biological prerequisites simply do not exist.

Patients with advanced, end-stage knee wear — whether described in clinical terms as grade IV disease or in plain language as bone-on-bone — fall outside the treatment's indicated use for this reason alone, regardless of other favourable factors.

One nuance deserves an honest explanation. Some clinics consider ChondroFiller liquid for patients with more diffuse OA not as a regenerative intervention but as a supportive measure — providing a viscoelastic matrix over the articular surface to cushion and protect. That is a different clinical intention from the focal-defect regenerative pathway, which operates under stricter eligibility requirements. The two should not be conflated: the regenerative pathway requires healthy surrounding borders and a functional cellular environment; the supportive use, where it is considered, is a separate clinical decision made on different grounds. The distinction matters, and a thorough assessment — including imaging review — will clarify which pathway, if any, is appropriate.

Collagen allergy and murine protein sensitivity

ChondroFiller is manufactured from murine-derived Type I collagen — sourced from rat tissue — which forms the scaffold matrix that gels within the knee joint after injection. For any patient with a confirmed hypersensitivity or allergy to collagen or to rat-derived proteins, this material composition creates an absolute contraindication, irrespective of how suitable the knee itself might otherwise appear.

This is a device-specific risk that differs from the standard cautions associated with intra-articular injections generally. A patient with no prior exposure to collagen-based products may be unaware that a sensitivity exists, which is why allergy and hypersensitivity history forms an essential part of the pre-treatment consultation — alongside imaging, joint assessment, and mechanical factors.

ChondroFiller's CE Class III classification — the highest risk tier under EU medical device regulation — reflects the regulatory weight placed on biocompatibility for an implantable biologic scaffold. That designation is precisely why allergy screening is a mandatory step rather than a discretionary one: the classification formally acknowledges that material-host interaction carries significant biological risk, and pre-injection assessment is structured to address it directly.

Active infection and inflammatory joint disease

Two distinct mechanisms make up this category of exclusion, and they point to different clinical outcomes: one creates a temporary barrier, the other reflects a more fundamental incompatibility between the joint environment and scaffold-based repair.

Active infection — deferrable, not permanent

Active infection in or around the knee — including septic arthritis and active systemic infection elsewhere — is a contraindication at the point of treatment. Introducing a biologic collagen scaffold into an infected joint carries a serious risk of spreading or entrenching infection. Clinical guidance is consistent on this point: the infection must be fully treated and resolved first, after which suitability for ChondroFiller can be reassessed. This is a reason to defer, not a permanent disqualifier.

Inflammatory arthritis — a more fundamental problem

Rheumatoid arthritis, psoriatic arthritis, gout, and related metabolic arthropathies fall into a different category. In these conditions, immune-mediated synovitis creates a chronically hostile joint environment — one in which the collagen matrix is likely to be degraded before host progenitor cells can colonise it. The very process the scaffold depends upon — orderly cell recruitment and matrix remodelling — is disrupted by ongoing inflammation.

Arthrofibrosis sits in a similar position: severe scarring and stiffening of the joint restricts both physical access to the defect site and the cellular environment required for integration.

Patients whose RA or gout appears stable or is managed with DMARDs are not automatically eligible on that basis alone. Whether inflammation is sufficiently controlled to permit scaffold integration is a question that requires individual consultant assessment — the disease label and the current joint state are separate considerations.

Mechanical prerequisites that must be met — or corrected — first

For patients who have had a previous ACL tear, meniscal surgery, or a corrected angular deformity, the prerequisites in this category are often the most personally relevant questions at assessment. Each is a structural demand ChondroFiller places on the knee — and failing any single one is not automatically a permanent disqualifier. Several can be addressed first, converting a 'not yet' into genuine candidacy.

Leg axis and malalignment

Coronal malalignment — varus or valgus deformity exceeding approximately 5° — concentrates load unevenly across the repair site. Even well-placed scaffold material cannot integrate reliably under that mechanical stress. Where correction is feasible, a high tibial or distal femoral osteotomy may be performed first, with ChondroFiller suitability reassessed once alignment is restored. These corrective procedures are a distinct surgical pathway, separate from the injection service itself.

Ligament stability

Untreated ligament laxity — including ACL insufficiency — generates shear forces that destabilise the scaffold during the early weeks of repair. Ligament reconstruction should precede or accompany treatment where joint instability is identified at assessment.

Meniscal integrity

Resection of more than one-third of total meniscal volume is a structural threshold. The meniscus distributes load across the articular surface; a significant deficit exposes any repair site to pressures it cannot sustain during healing.

Opposing surface and joint mobility

The articular surface on the opposite side of the joint must show no more than Outerbridge Grade II change — a 'kissing lesion' on that surface is an exclusion. Severe joint stiffness or contracture also disqualifies, as restricted mobility limits both access to the defect and the conditions needed for scaffold integration.

Objective assessment — including imaging analysis and, where indicated, gait evaluation via MAI Motion® — can identify these mechanical factors before any treatment decision is made.

Systemic health conditions and next steps for borderline cases

Several systemic health conditions create either a firm barrier to treatment or a reason to defer — and the distinction matters for patients who are uncertain where they stand.

Permanent exclusions. Active malignancy is an absolute contraindication, as is a tumour in the vicinity of the knee. Immunosuppression — whether medication-induced (chemotherapy, long-term high-dose corticosteroids) or disease-related — reduces the body's capacity to recruit and differentiate the progenitor cells the scaffold depends upon. Hematopoietic disorders and neurological conditions are listed exclusions for similar reasons, reflecting impaired healing competence or procedural risk.

Temporary exclusions. Pregnancy and breastfeeding are contraindications in the absence of safety data for these groups; the exclusion ends when the relevant period does. Patients on anticoagulant therapy, or with a bleeding disorder that cannot be safely managed, are also unable to proceed at present — though those who can pause anticoagulation under medical supervision may be reassessed once that is confirmed.

Defect size ceiling. The injectable form is sized for defects up to 3 cm²; defects that substantially exceed this, or that involve deep subchondral loss beyond the device's treatment envelope, fall outside the current indication regardless of other factors.

Many patients who assume they are not suitable have not yet had a formal assessment. Several of the barriers described across this article — malalignment, meniscal deficit, ligament instability, active infection, and anticoagulation — can be corrected or resolved, converting a current exclusion into future eligibility. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral; a structured suitability review is the only reliable way to establish which category applies. Book an assessment at lincolnshireknee.co.uk.